Lamivudine — Membership Pricing

Other medications in Infections

• Ledipasvir
• Linezolid
• Loracarbef
• Meropenem
• Minocycline
• Moxifloxacin
• Ofloxacin
• Oritavancin

About Lamivudine

Lamivudine is a vital medication used to manage chronic viral infections like HIV and Hepatitis B. Understanding its role in your health journey is crucial, and so is finding affordable access. With TheDrugClub, members can often discover significant savings on essential prescriptions like lamivudine, helping to make your treatment more manageable.

Lamivudine, often known by its brand name Epivir or Epivir-HBV, is an antiviral medication prescribed to combat two significant viral infections: Human Immunodeficiency Virus (HIV) and chronic Hepatitis B virus (HBV) infection. For HIV, it's typically used as part of a combination therapy, helping to reduce the amount of virus in the body and improve the immune system. For chronic Hepatitis B, it works to slow down the progression of the disease and reduce liver damage.

Lamivudine belongs to a class of drugs called nucleoside reverse transcriptase inhibitors (NRTIs). When HIV or HBV replicates, they use an enzyme called reverse transcript

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Lamivudine is approved for (FDA label)

Lamivudine tablets (HBV) are indicated for the treatment of chronic hepatitis B virus (HBV) infection associated with evidence of hepatitis B viral replication and active liver inflammation [see Clinical Studies ( 14.1 , 14.2 )]. The following points should be considered when initiating therapy with lamivudine tablets (HBV): • Due to high rates of resistance development in treated patients, initiation of treatment with lamivudine tablets (HBV) should only be considered when the use of an alternative antiviral agent with a higher genetic barrier to resistance is not available or appropriate. • Lamivudine tablets (HBV) have not been evaluated in patients co-infected with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis delta virus.

Source: Read the full FDA label on DailyMed. Label effective date: July 29, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Lamivudine (FDA label)

WARNING: EXACERBATIONS OF HEPATITIS B and RISK OF HIV-1 RESISTANCE IF LAMIVUDINE TABLETS (HBV) IS USED IN PATIENTS WITH UNRECOGNIZED OR UNTREATED HIV-1 INFECTION Severe acute exacerbations of hepatitis B have been reported in patients who have discontinued anti-hepatitis B therapy (including lamivudine tablets (HBV). Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue anti-hepatitis B therapy. If appropriate, initiation of anti-hepatitis B therapy may be warranted [see Warnings and Precautions (5.1) ]. Lamivudine tablets (HBV) are not approved for the treatment of human immunodeficiency virus type 1 (HIV-1) infection because the lamivudine dosage in lamivudine tablets (HBV) is subtherapeutic and monotherapy is inappropriate for the treatment of HIV-1 infection. HIV-1 resistance may emerge in chronic hepatitis B-infected patients with unrecognized or untreated HIV-1 infection. HIV counseling and testing should be offered to all patients before beginning treatment with lamivudine tablets (HBV) and periodically during treatment [see Warnings and Precautions (5.2) ]. WARNING: EXACERBATIONS OF HEPATITIS B and RISK OF HIV-1 RESISTANCE IF LAMIVUDINE TABLETS (HBV) IS USED IN PATIENTS WITH UNRECOGNIZED OR UNTREATED HIV-1 INFECTION See full prescribing information for complete boxed warning • Severe acute exacerbations of hepatitis B have been reported in patients who have discontinued anti-hepatitis B therapy (including lamivudine tablets (HBV).

Source: FDA prescribing information (DailyMed). Set ID: 6bd6b9da-df69-46db-813e-4e7f3bdecf95. SPL document ID: 57c05c90-abd7-b7ab-e063-6394a90a93db. Label effective date: July 29, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Lamivudine (FDA label)

• Lamivudine tablets (HBV): 100 mg are pink colored, capsule shaped, biconvex, film coated tablets, debossed with ‘37’ on one side and ‘I’ on the other side. • Tablets: 100 mg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 6bd6b9da-df69-46db-813e-4e7f3bdecf95. SPL document ID: 57c05c90-abd7-b7ab-e063-6394a90a93db. Label effective date: July 29, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Lamivudine (FDA label)

The following adverse reactions are discussed in other sections of the labeling: • Exacerbations of hepatitis B after discontinuation of treatment [see Warnings and Precautions (5.1) ]. • Risk of emergence of resistant HIV-1 infection [see Warnings and Precautions (5.2) ]. • Risk of emergence of resistant HBV infection [see Warnings and Precautions (5.3) ]. • Lactic acidosis and severe hepatomegaly with steatosis [see Warnings and Precautions (5.4) ]. The most common reported adverse reactions in those receiving lamivudine tablets (HBV) (incidence greater than or equal to 10% and reported at a rate greater than placebo) were ear, nose, and throat infections; sore throat; and diarrhea. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Hetero Labs Limited at 1-866-495-1995 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Source: FDA prescribing information (DailyMed). Set ID: 6bd6b9da-df69-46db-813e-4e7f3bdecf95. SPL document ID: 57c05c90-abd7-b7ab-e063-6394a90a93db. Label effective date: July 29, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Lamivudine (FDA label)

Lamivudine tablets (HBV) are contraindicated in patients with a previous hypersensitivity reaction to lamivudine. Lamivudine tablets (HBV) is contraindicated in patients with previous hypersensitivity reaction to lamivudine. (4)

Source: FDA prescribing information (DailyMed). Set ID: 6bd6b9da-df69-46db-813e-4e7f3bdecf95. SPL document ID: 57c05c90-abd7-b7ab-e063-6394a90a93db. Label effective date: July 29, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Lamivudine (FDA label)

• Emergence of Resistance-Associated HBV Substitutions: Consider a switch to an alternative regimen if serum HBV DNA remains detectable after 24 weeks of treatment. ( 2.6 , 5.3 ) • Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues. ( 5.4 ) 5.1 Exacerbations of Hepatitis after Discontinuation of Treatment Clinical and laboratory evidence of exacerbations of hepatitis have occurred after discontinuation of lamivudine. These exacerbations have been detected primarily by serum ALT elevations in addition to re-emergence of HBV DNA commonly observed after stopping treatment; see Table 4 for more information regarding frequency of posttreatment ALT elevations [see Adverse Reactions (6.1) ]. Although most events appear to have been self-limited, fatalities have been reported in some cases. The causal relationship to discontinuation of lamivudine treatment is unknown.

Source: FDA prescribing information (DailyMed). Set ID: 6bd6b9da-df69-46db-813e-4e7f3bdecf95. SPL document ID: 57c05c90-abd7-b7ab-e063-6394a90a93db. Label effective date: July 29, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Lamivudine (FDA label)

Sorbitol: Coadministration of lamivudine and sorbitol may result in decreased lamivudine concentrations; when possible, avoid chronic coadministration. Consider more frequent monitoring of HBV viral load when chronic coadministration cannot be avoided. (7.2) 7.1 Drugs Inhibiting Organic Cation Transporters Lamivudine is predominantly eliminated in the urine by active organic cationic secretion. The possibility of interactions with other drugs administered concurrently should be considered, particularly when their main route of elimination is active renal secretion via the organic cationic transport system (e.g., trimethoprim) [see Clinical Pharmacology (12.3)]. No data are available regarding interactions with other drugs that have renal clearance mechanisms similar to that of lamivudine. 7.2 Sorbitol Coadministration of single doses of lamivudine and sorbitol resulted in a sorbitol dose-dependent reduction in lamivudine exposures. When possible, avoid use of sorbitol-containing medicines with lamivudine [see Clinical Pharmacology (12.3]. Consider more frequent monitoring of HBV viral load when chronic coadministration cannot be avoided.

Source: FDA prescribing information (DailyMed). Set ID: 6bd6b9da-df69-46db-813e-4e7f3bdecf95. SPL document ID: 57c05c90-abd7-b7ab-e063-6394a90a93db. Label effective date: July 29, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.